Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
Chi Hun Song1, Minchan Jeong1, Hyukmin In1
1Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea.
Abstract:
In cancer treatment, the first-generation, cytotoxic drugs, though effective against cancer cells, also harmed healthy ones. The second-generation targeted cancer cells precisely to inhibit their growth. Enter the third-generation, consisting of immuno-oncology drugs, designed to combat drug resistance and bolster the immune system's defenses. These advanced therapies operate by obstructing the uncontrolled growth and spread of cancer cells through the body, ultimately eliminating them effectively. Within the arsenal of cancer treatment, monoclonal antibodies offer several advantages, including inducing cancer cell apoptosis, precise targeting, prolonged presence in the body, and minimal side effects. A recent development in cancer therapy is Antibody-Drug Conjugates (ADCs), initially developed in the mid-20th century. The second generation of ADCs addressed this issue through innovative antibody modification techniques, such as DAR regulation, amino acid substitutions, incorporation of non-natural amino acids, and enzymatic drug attachment. Currently, a third generation of ADCs is in development. This study presents an overview of 12 available ADCs, reviews 71 recent research papers, and analyzes 128 clinical trial reports. The overarching objective is to gain insights into the prevailing trends in ADC research and development, with a particular focus on emerging frontiers like potential targets, linkers, and drug payloads within the realm of cancer treatment.
Insights
Third-generation Antibody-Drug Conjugates (ADCs) represent advanced cancer therapies targeting drug resistance and enhancing immune response. This study analyzes current trends in ADC research, focusing on novel targets, linkers, and payloads for improved cancer treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- First-generation cytotoxic drugs lacked specificity, harming healthy cells alongside cancerous ones.
- Second-generation therapies introduced targeted approaches to inhibit cancer cell growth.
- Third-generation immuno-oncology drugs aim to overcome drug resistance and activate the immune system against cancer.
Purpose of the Study:
- To provide an overview of 12 available Antibody-Drug Conjugates (ADCs).
- To review 71 recent research papers and analyze 128 clinical trial reports on ADCs.
- To identify prevailing trends and emerging frontiers in ADC research and development for cancer treatment.
Main Methods:
- Comprehensive literature review of recent research papers.
- Analysis of clinical trial reports focusing on Antibody-Drug Conjugates (ADCs).
- Systematic overview of currently available ADCs and their characteristics.
Main Results:
- Monoclonal antibodies offer advantages like targeted delivery, apoptosis induction, and reduced side effects.
- Second-generation ADCs improved upon earlier designs through antibody modification techniques.
- Third-generation ADCs are under development, indicating continuous innovation in the field.
Conclusions:
- Antibody-Drug Conjugates (ADCs) are a significant advancement in cancer therapy, offering improved specificity and efficacy.
- Ongoing research focuses on optimizing targets, linkers, and drug payloads to enhance ADC performance.
- The evolution of ADCs, from early cytotoxic agents to advanced immuno-oncology conjugates, highlights a promising trajectory in cancer treatment research.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...